Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501200 | 0.90 | MAPT (0.45) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL321101 | 0.88 | KMT2A (0.43) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL321257 | 0.88 | MAPT (0.43) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL1573289 | 0.88 | HTT (0.47) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL13918696 | 0.86 | MAPT (0.53) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL27737744 | 0.86 | MAPT (0.46) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL27758529 | 0.84 | MAPT (0.45) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL3597834 | 0.84 | HTT (0.52) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL320960 | 0.83 | MAPT (0.39) | KMT2AMAPTMEN1USP2ALDH1A1 | |
| SCHEMBL320893 | 0.83 | MAPT (0.46) | KMT2AMAPTMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| EP-2590975-B1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-08-19 | — | — | EP | disclosed |
| US-8859544-B2 | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| CN-101384258-B | FGF Receptor Agonist Dimeric Compounds | SANOFI AVENTIS | 2013-06-26 | — | — | CN | disclosed |
| EP-2590975-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| CN-103080112-A | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | SANOFI SA | 2013-05-01 | — | — | CN | disclosed |
| WO-2012004731-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-01-12 | — | — | WO | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
| CN-101384258-A | FGF receptor agonist dimeric compounds | SANOFI AVENTIS (FR) | 2009-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | KMT2A 3395/4885MAPT 3588/4885MEN1 621/4885 |
| US-20130116249-A1 | INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, INMT, IDO1 | KMT2A 1538/4885MAPT 961/4885MEN1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.